a Delaware limited

Featured in: Favicon

benzinga.com Favicon

streetinsider.com Favicon

advfn.com

marketscreener.com

Articles

General Statement of Acquisition of Beneficial Ownership: [Amend]

Oct 2, 2024 | mx.advfn.com | a Delaware limited |As Trustee |ized Signatory

SECURITIES AND EXCHANGE COMMISSIONWashington,D.C. 20549SCHEDULE 13D/A(Amendment No. 1)Under the Securities Exchange Act of 1934ZurnElkay Water Solutions Corporation(Name of Issuer)Common Stock(Title of Class of Securities)98983L108(CUSIP Number)Brooke R.
Amended Statement of Ownership (sc 13g/a)

Aug 9, 2024 | de.advfn.com | a Delaware limited

THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12)* Genasys Incorporated (formally: LRAD Corporation) (Name of Issuer) Common Stock, Par Value $.00001 (Title of Class of Securities) 36872P103 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: [X] Rule 13d-1(b) [ ]...
Form SC 13D/A Vera Therapeutics, Inc. Filed by: Sofinnova Venture Partners X, L.P.

Mar 26, 2024 | streetinsider.com | Sofinnova Management X |Sofinnova Management X-A |a Delaware limited

1. SPY2. STOK3. AAPL4. ADBE5. F6. MSFT7. TSLA8. MTDR9. GME10. VKTX Tweet Share E-mail0 sharesSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549SCHEDULE 13D(RULE 13d-101)INFORMATION TO BE INCLUDED IN STATEMENTS FILEDPURSUANT TO RULE 13d-1(a)AND AMENDMENTS THERETO FILED PURSUANT TO RULE13d-2(a)(Amendment No. 4)*Vera Therapeutics, Inc. (Name of Issuer)Class A Common Stock, $0.001 par value(Title of Class of Securities)92337R101(CUSIP Number)Nathalie AuberSofinnova Investments, Inc.
Form SC 13D/A Karuna Therapeutics, Filed by: Sofinnova Venture Partners X, L.P.

Feb 6, 2023 | streetinsider.com | Sofinnova Management X |a Delaware limited |James Healy |Sofinnova Management X-A

Form SC 13D/A Karuna Therapeutics, Filed by: Sofinnova Venture Partners X, L.P.February 6, 2023 6:02 AM EST Tweet Share E-mailGet inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. SECURITIES AND EXCHANGE COMMISSIONINFORMATION TO BE INCLUDED IN STATEMENTS FILEDPURSUANT TO RULE 13d-1(a)AND AMENDMENTS THERETO FILED PURSUANT TO RULE13d-2(a)Karuna Therapeutics, Inc. Common Stock, $0.0001 par value(Title of Class of Securities) Sofinnova Investments, Inc.